Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EPS (Weighted Average and Diluted) (2016 - 2026)

Cytosorbents filings provide 9 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.09 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 35.71% to -$0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.13, a 65.79% increase, with the full-year FY2025 number at -$0.13, up 65.79% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.09 in Q4 2025 for Cytosorbents, down from -$0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q2 2025 to a low of -$0.28 in Q3 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.12 (2021), compared with a mean of -$0.13.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 1331.96% in 2021 and later soared 137.5% in 2025.
  • Cytosorbents' EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then skyrocketed by 92.0% to -$0.02 in 2022, then plummeted by 500.0% to -$0.12 in 2023, then decreased by 16.67% to -$0.14 in 2024, then skyrocketed by 35.71% to -$0.09 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.09 (Q4 2025), -$0.05 (Q3 2025), and $0.03 (Q2 2025) per Business Quant data.